QLi5 TherapeuticsQLi5: Novel Proteasome Inhibitor Platform company
QLi5 Therapeutics is a biotech company pioneering next-generation proteasome inhibitors to address unmet medical needs in oncology, hematology and immunology disorders. Developed in collaboration with Nobel laureate Prof. Robert Huber, QLi5 develops novel series of proteasome inhibitors with flexible selectivity profile, enabling broad therapeutic applications.
As a key regulator of cellular homeostasis and a key modulator for various cellular functions, dysregulation of proteasome makes a root cause of many diseases, including cancer and autoimmune disorders. With novel structure-based chemistry, QLi5 is advancing its proteasome inhibitors as a next-generation ADC payload platform. QLi5's proteasome inhibitor has demonstrated standalone single agent therapeutic window, a prerequisite profile for a novel payload platform.
QLi5 aims to create a next generation ADC payload platform to help patients who do not respond to the current standard of care therapies by providing an orthogonal option for treatment.
Link to QLi5 Therapeutics: https://qli5tx.com/